Page 114 - 《中国药房》2023年19期

[ 4 ] TANI N，KAWAI N，CHONG Y，et al. Susceptibility of [14] ZHAO Y H，HUANG G L，HE W J，et al. Efficacy and
epidemic viruses to neuraminidase inhibitors and treatment- safety of single-dose antiviral drugs for influenza treat‐
emergent resistance in the Japanese 2019-20 influenza ment：a systematic review and network meta-analysis[J]. J
season[J]. J Infect，2022，84（2）：151-157. Med Virol，2022，94（7）：3270-3302.
[ 5 ] ISON M G，PORTSMOUTH S，YOSHIDA Y，et al. Early [15] International Society for Pharmacoeconomics and Out‐
treatment with baloxavir marboxil in high-risk adolescent comes Research. Cost-effectiveness analysis of baloxavir
and adult outpatients with uncomplicated influenza marboxil as seasonal influenza treatment compared to
（CAPSTONE-2） ：a randomised，placebo-controlled， oseltamivir in China[EB/OL]. [2022-12-31]. https：//www.
phase 3 trial[J]. Lancet Infect Dis，2020，20（10）：1204- ispor. org/docs/default-source/euro2021/ispor-poster-1108-
1214. pdf.
[ 6 ] ZHANG W X，XU H F，GUAN S X，et al. Frequency and [16] International Society for Pharmacoeconomics and Out‐
distribution of H1N1 influenza A viruses with oseltamivir- comes Research. A cost-effectiveness analysis for in-
resistant mutations worldwide before and after the 2009 fluenza virus infection with oseltamivir or baloxavir in
pandemic[J]. J Med Virol，2022，94（9）：4406-4416. Japan[EB/OL]. [2022-12-31]. https：//www.ispor.org/
[ 7 ] YANG T R. Baloxavir marboxil：the first cap-dependent docs/default-source/intl2019/poster_naoto-nakagawa-pdf.
endonuclease inhibitor for the treatment of influenza[J]. [17] International Society for Pharmacoeconomics and Out‐
comes Research. Cost-effectiveness and budget impact of
Ann Pharmacother，2019，53（7）：754-759.
baloxavir marboxil in the netherlands based on post-covid
[ 8 ] YOSHINO Y，KITAZAWA T，OTA Y. Clinical efficacy of
influenza season scenario[EB/OL]. [2022-12-31]. https：//
baloxavir marboxil in the treatment of seasonal influenza
www. ispor. org/docs/default-source/euro2022/isporxoflu-
in adult patients：a prospective observational study[J]. Int
zadef-pdf.
J Gen Med，2020，13：735-741.
[18] SKRZECZEK A，IKEOKA H，HIROTSU N，et al. Cost-
[ 9 ] TAIEB V，IKEOKA H，MA F，et al. A network meta-
effectiveness of baloxavir marboxil compared to lanina-
analysis of the efficacy and safety of baloxavir marboxil
mivir for the treatment of influenza in Japan[J]. J Infect
versus neuraminidase inhibitors for the treatment of influen-
Chemother，2021，27（2）：296-305.
za in otherwise healthy patients[J]. Curr Med Res Opin，
[19] DRONOVA M，IKEOKA H，ITSUMURA N，et al. Cost-
2019，35（8）：1355-1364.
effectiveness of baloxavir marboxil compared with lanina‐
[10] KUO Y C，LAI C C，WANG Y H，et al. Clinical efficacy
mivir for the treatment of influenza in patients at high risk
and safety of baloxavir marboxil in the treatment of
for complications in Japan[J]. Curr Med Res Opin，2021，
influenza：a systematic review and meta-analysis of ran‐
37（7）：1135-1148.
domized controlled trials[J]. J Microbiol Immunol Infect，
[20] 成人流行性感冒抗病毒治疗共识专家组. 成人流行性感
2021，54（5）：865-875.
冒抗病毒治疗专家共识[J]. 中华传染病杂志，2022，40
[11] LIU J W，LIN S H，WANG L C，et al. Comparison of anti‐
（11）：641-655.
viral agents for seasonal influenza outcomes in healthy
Expert Group on Consensus for Antiviral Treatment of In‐
adults and children：a systematic review and network
fluenza in Adults. Expert consensus on antiviral treatment
meta-analysis[J]. JAMA Netw Open，2021，4 （8） ：
of influenza in adults[J]. Chin J Infect Dis，2022，40（11）：
e2119151.
641-655.
[12] TAIEB V，IKEOKA H，WOJCIECHOWSKI P，et al. Effi‐ [21] UYEKI T M，BERNSTEIN H H，BRADLEY J S，et al.
cacy and safety of baloxavir marboxil versus neuramini‐ Clinical practice guidelines by the Infectious Diseases
dase inhibitors in the treatment of influenza virus infection Society of America：2018 update on diagnosis，treatment，
in high-risk and uncomplicated patients：a Bayesian net‐ chemoprophylaxis，and institutional outbreak management
work meta-analysis[J]. Curr Med Res Opin，2021，37（2）： of seasonal influenza A[J]. Clin Infect Dis，2019，68（6）：
225-244. 895-902.
[13] TEJADA S，TEJO A M，PEÑA-LÓPEZ Y，et al. Neura- [22] Committee on Infectious Diseases. Recommendations for
minidase inhibitors and single dose baloxavir are effective prevention and control of influenza in children，2021-2022
and safe in uncomplicated influenza：a meta-analysis of [J]. Pediatrics，2021，148（4）：e2021053745.
randomized controlled trials[J]. Expert Rev Clin Pharma‐ （收稿日期：2023-03-17 修回日期：2023-08-18）
col，2021，14（7）：901-918. （编辑：刘明伟）

· 2408 · China Pharmacy 2023 Vol. 34 No. 19 中国药房 2023年第34卷第19期